Actively Recruiting
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
Led by Beijing Anlong Biopharmaceutical Co., Ltd. · Updated on 2024-12-05
21
Participants Needed
1
Research Sites
237 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
CONDITIONS
Official Title
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
- The subject or their legal representative agrees to participate in this study and signs a written ICF.
- The subjects are willing and able to follow planned visits and procedures.
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese Academy of Medical Sciences & Peking Union Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
A
AnlongBio
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here